Showing results (61-70 of 511) with videos related to

Sort By:
Pageof 52
Crohn'S & Colitis 360|July 16, 2025
Sex Disparities in Treatment Trajectories of Inflammatory Bowel Disease Are Associated With Diagnostic DelayLea Pueschel, Melanie Bathon, Ursula Seidler, et al.
Crohn'S & Colitis 360|December 16, 2024
Predictive Model for Outcomes in Inflammatory Bowel Disease Patients Receiving Maintenance Infliximab TherapyRochelle Wong, Paris Charilaou, Amy Hemperly, et al.
Crohn'S & Colitis 360|February 7, 2025
Reactions, Reality, and Resilience in Adults with Crohn's Disease: A Qualitative StudyKatherine Jones, Katherine Baker, Garry A Tew, et al.
Crohn'S & Colitis 360|February 7, 2025
Clinical Features of Thiopurine-Induced Acute Pancreatitis: Comparison Between Patients With and Without Inflammatory Bowel DiseaseTomofumi Oizumi, Yosuke Toya, Shunichi Yanai, et al.
Crohn'S & Colitis 360|January 29, 2025
Exploring Dual-Targeted Therapy in the Management of Moderate to Severe Inflammatory Bowel Disease: A Retrospective StudySonya Bhaskar, Zachary Makovich, Rahul Mhaskar, et al.
Crohn'S & Colitis 360|January 21, 2025
Real-World Impact of Uncontrolled Symptoms and Suboptimal Treatment Response in Patients With Crohn's Disease in the United States and EuropeJim Kershaw, Myrlene Sanon, Sumesh Kachroo, et al.
Crohn'S & Colitis 360|January 21, 2025
Intravenous Steroids Do Not Improve Short-Term Outcomes of Patients With Crohn's Disease Presenting With an Acute Small Bowel ObstructionMariely Garcia, Anketse Debebe, Farhan Mahmood, et al.
Crohn'S & Colitis 360|October 20, 2023
Vedolizumab in Mild-to-Moderate Crohn's Disease Patients Naïve to Biological Therapy: A Multicentric Observational StudyAdriana Zanoni Dotti, Daniela Oliveira Magro, Eduardo Garcia Vilela, et al.
Crohn'S & Colitis 360|October 30, 2023
Extraintestinal Manifestations of Inflammatory Bowel Disease Are Associated With Increased Biologic CyclingMadeline Alizadeh, Osman Ali, Raymond K Cross
Crohn'S & Colitis 360|March 28, 2024
Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up StudyThea H Wiken, Marte L Høivik, Karoline Anisdahl, et al.
Pageof 52